HRTX Q1 2023 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+26.3% YoY

Gross Profit

$13M43.1% margin

Operating Income

-$33M-111.6% margin

Net Income

-$33M-110.6% margin

EPS (Diluted)

$-0.27

QoQ Revenue Growth

-1.4%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$221M

Total Liabilities

$232M

Stockholders' Equity

-$11M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$23M	+26.3%
Gross Profit	$13M	$12M	+5.4%
Operating Income	-$33M	-$63M	+47.5%
Net Income	-$33M	-$64M	+48.7%

Revenue Segments

C I N V A N T I

$23M78%

Z Y N R E L E F

$4M12%

S U S T O L

$3M10%